Given that hypoxia is a persistent physiological feature of many different solid tumors and a
key driver for cancer malignancy, it is thought to be a major target in cancer treatment …

In order to meet the high energy demand, a metabolic reprogramming occurs in cancer cells.
Its role is crucial in promoting tumor survival. Among the substrates in demand, oxygen is …

Hypoxia, low oxygen (O2) level, is a hallmark of solid cancers, especially hepatocellular
carcinoma (HCC), one of the most common and fatal cancers worldwide. Hypoxia …

Most patients with advanced triple-negative breast cancer (TNBC) develop drug resistance.
MYC and MCL1 are frequently co-amplified in drug-resistant TNBC after neoadjuvant …

Intratumoral hypoxia (reduced O 2 availability) is a common finding in human cancer and
leads to increased activity of hypoxia-inducible factors (HIFs), which regulate the expression …

Poor response to cancer therapy due to resistance remains a clinical challenge. The present
study establishes a widely prevalent mechanism of resistance to gemcitabine in pancreatic …

Abstract Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer
drug target. Many recent studies have provided convincing evidences of strong correlation …

Glioblastoma is the most aggressive form of brain tumor in adults and is characterized by the
presence of hypervascularization and necrosis, both caused by a hypoxic …

Insufficient tissue oxygenation, or hypoxia, contributes to tumor aggressiveness and has a
profound impact on clinical outcomes in cancer patients. At decreased oxygen tensions …

Hypoxia-inducible factors (HIFs) are master regulators of oxygen homeostasis that match O2
supply and demand for each of the 50 trillion cells in the adult human body. Cancer cells co …